Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;86(1):52-58.

Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus

Suzanne L Benedict  1 , Orla M Mahony  1 , Talon S McKee  1 , Philip J Bergman  1
Affiliations

Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus

Suzanne L Benedict et al. Can J Vet Res. 2022 Jan.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Can J Vet Res. 2023 Apr;87(2):152. Can J Vet Res. 2023. PMID: 37020576 Free PMC article.

Abstract
in English, French

The aim of this study was to investigate the effect of bexagliflozin on glycemic control in poorly regulated diabetic cats and to evaluate for adverse events associated with this medication. Sodium-glucose cotransporter 2 inhibitors are a newer class of drugs used in the management of humans with type 2 diabetes mellitus. The objective of this study was to evaluate the effect of the orally administered drug, bexagliflozin in a group of poorly regulated diabetic cats over a 4-week study period. Five client-owned cats with poorly controlled diabetes mellitus receiving insulin therapy were enrolled. Bexagliflozin was administered once daily. Serum fructosamine, serum biochemistry profile, and 10-hour blood glucose curves were assessed at baseline (Day 0), Day 14, and Day 28. All cats had a significant reduction in insulin dose requirement (P = 0.015) and insulin was discontinued in 2 cats. There was a significant decrease in blood glucose concentration obtained from blood glucose concentration curves during the study period (P = 0.022). Serum fructosamine decreased in 4 of the 5 cats with a median decrease of 152 μmol/L (range: 103 to 241 μmol/L), which was not statistically significant (P = 0.117). No cats had any documented episodes of hypoglycemia. Adverse effects were mild. The addition of bexagliflozin significantly improved diabetic management in this group of cats.

Le but de cette étude était d’étudier l’effet de la bexagliflozine sur la maitrise de la glycémie chez les chats diabétiques mal régulés et d’évaluer les événements indésirables associés à ce médicament. Les inhibiteurs du cotransporteur sodium-glucose 2 sont une nouvelle classe de médicaments utilisés dans la prise en charge des personnes atteintes de diabète de type 2. L’objectif de cette étude était d’évaluer l’effet du médicament administré par voie orale, la bexagliflozine, dans un groupe de chats diabétiques mal régulés sur une période d’étude de 4 semaines. Cinq chats appartenant à des clients atteints de diabète sucré mal maitrisé et recevant une insulinothérapie ont été inclus. La bexagliflozine a été administrée une fois par jour. La fructosamine sérique, le profil biochimique sérique et les courbes de glycémie sur 10 heures ont été évalués au départ (jour 0), au jour 14 et au jour 28. Tous les chats ont présenté une réduction significative de la dose d’insuline requise (P = 0,015) et l’insuline a été interrompue chez deux chats. Il y avait une diminution significative de la concentration de glucose dans le sang obtenue à partir des courbes de concentration de glucose dans le sang au cours de la période d’étude (P = 0,022). La fructosamine sérique a diminué chez 4 des 5 chats avec une diminution médiane de 152 μmol/L (plage : 103 à 241 μmol/L), ce qui n’était pas statistiquement significatif (P = 0,117). Aucun chat n’a eu d’épisodes documentés d’hypoglycémie. Les effets indésirables étaient légers. L’ajout de bexagliflozine a considérablement amélioré la gestion du diabète dans ce groupe de chats.(Traduit par Docteur Serge Messier).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serial blood glucose concentrations of the blood glucose curves (BGCs) of diabetic cats (N = 5) before (Day 0) and after receiving oral bexagliflozin daily for 2 wk (Day 14) and 4 wk (Day 28) during the 4-week study period. Dots represent the mean blood glucose (MBG) concentration obtained from the 10-hour BGCs of each cat on Days 0, 14, and 28. Horizontal line represents median values of the MBG concentration obtained during the 10-hour BGC of all cats on Days 0, 14, and 28.
Figure 2
Figure 2
Fructosamine concentrations (median) of diabetic cats (N = 5) before (Day 0) and after receiving oral bexagliflozin daily for 2 wk (Day 14) and 4 wk (Day 28) during the 4-week study period. Dots represent the MBG concentration. Horizontal line represents median.
Figure 3
Figure 3
Insulin dose (median) administered every 12 h to diabetic cats (N = 5) before (Day 0) and after receiving oral bexagliflozin daily for 2 wk (Day 14) and 4 wk (Day 28) during the 4-week study period. Dots represent the MBG concentration. Horizontal line represents median.
Figure 4
Figure 4
Beta-hydroxybutyrate (β-OHB) values (median) of diabetic cats (N = 5) before (Day 0) and after receiving oral bexagliflozin daily for 2 wk (Day 14) and 4 wk (Day 28) during the 4-week study period. Dots represent the MBG concentration. Horizontal line represents median.
See this image and copyright information in PMC

References

    1. O’Neill DG, Gostelow R, Orme C, et al. Epidemiology of diabetes mellitus among 193 435 cats attending primary-care veterinary practices in England. J Vet Int Med. 2016;30:964–972. - PMC - PubMed
    1. Sparkes AH, Cannon M, Church D, et al. ISFM consensus guidelines on the practical management of diabetes mellitus in cats. J Feline Med Surg. 2015;17:235–250. - PMC - PubMed
    1. Aptekmann KP, Armstrong J, Coradini M, Rand J. Owner experiences in treating dogs and cats diagnosed with diabetes mellitus in the United States. J Am Anim Hosp Assoc. 2014;50:247–253. - PubMed
    1. Niessen SJM, Powney S, Guitian J, et al. Evaluation of a quality-of-life tool for cats with diabetes mellitus. J Vet Intern Med. 2010;24:1098–1105. - PubMed
    1. Niessen SJM, Hazuchova K, Powney SL, et al. The big pet diabetes survey: Perceived frequency and triggers for euthanasia. Vet Sci. 2017;4:27. - PMC - PubMed

MeSH terms